Fermentalg Logo

Fermentalg

ISIN

FR0011271600

Ticker

ALGAE

Sector

Health Care

Sub-Industry

Biotechnology

Country

France

Year Founded

2009

About Fermentalg

Company Description

Fermentalg is a pioneering biotechnology company specializing in the production and commercialization of innovative solutions derived from microalgae. Founded in 2009 and headquartered in Libourne, France, Fermentalg leverages its cutting-edge expertise in the cultivation and transformation of microalgae to address some of the most pressing environmental and health challenges of our time.

Fermentalg's mission is to unlock the potential of microalgae to provide sustainable alternatives in various industries, including nutrition, health, and the environment. The company's unique technology platform enables the production of high-value compounds such as Omega-3 fatty acids, natural pigments, and proteins, which are essential for human health and nutrition. These products are designed to meet the growing consumer demand for natural, sustainable, and health-promoting ingredients.

Served Area

Europe

Headquarters

4 Rue Rivière
33500, Libourne
France

Financial statements

Download as Excel
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 41,886,000.00 60,876,000.00 57,540,000.00
Noncurrent Assets N/A 23,233,000.00 27,165,000.00 31,240,000.00
Property Plant And Equipment N/A 13,175,000.00 12,814,000.00 12,582,000.00
Intangible Assets Other Than Goodwill N/A 9,932,000.00 12,636,000.00 14,365,000.00
Investment Accounted For Using Equity Method N/A 0.00 1,542,000.00 3,993,000.00
Deferred Tax Assets N/A 0.00 0.00 0.00
Other Noncurrent Assets N/A 125,000.00 173,000.00 301,000.00
Current Assets N/A 18,653,000.00 33,711,000.00 26,300,000.00
Inventories N/A 2,020,000.00 2,907,000.00 6,411,000.00
Current Trade Receivables N/A 1,243,000.00 1,541,000.00 1,344,000.00
Other Current Receivables N/A 3,550,000.00 3,253,000.00 2,643,000.00
Cash and cash equivalents 8,024,000.00 11,840,000.00 26,010,000.00 15,902,000.00
Equity And Liabilities N/A 41,886,000.00 60,876,000.00 57,540,000.00
Equity 18,569,000.00 20,304,000.00 47,002,000.00 41,980,000.00
Issued Capital N/A 1,011,000.00 1,599,000.00 1,684,000.00
Share Premium N/A 18,295,000.00 44,819,000.00 44,010,000.00
Reserve Of Equity Component Of Convertible Instruments N/A 1,051,000.00 473,000.00 473,000.00
Equity Attributable To Owners Of Parent N/A 20,304,000.00 47,002,000.00 41,980,000.00
Noncontrolling Interests N/A 0.00 0.00 0.00
Noncurrent Liabilities N/A 11,255,000.00 9,589,000.00 10,978,000.00
Other Noncurrent Liabilities N/A 0.00 218,000.00 538,000.00
Current Liabilities N/A 10,327,000.00 4,286,000.00 4,583,000.00
Other Shortterm Provisions N/A 230,000.00 230,000.00 190,000.00
Trade And Other Current Payables To Trade Suppliers N/A 1,481,000.00 1,428,000.00 1,522,000.00
Current Tax Liabilities Current N/A 0.00 0.00 0.00
Other Current Liabilities N/A 3,519,000.00 2,023,000.00 2,040,000.00
Line item in (eur) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Interest Income On Cash And Cash Equivalents 56,000.00 51,000.00 17,000.00
Other Revenue 1,456,000.00 1,149,000.00 1,387,000.00
Revenue From Contracts With Customers 2,205,000.00 5,647,000.00 7,648,000.00
Expense From Sharebased Payment Transactions With Employees -139,000.00 56,000.00 202,000.00
Profit Loss From Operating Activities -6,180,000.00 -5,856,000.00 -9,030,000.00
Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method N/A -321,000.00 -459,000.00
Income Tax Expense Continuing Operations 0.00 0.00 0.00
Profit (loss) -6,878,000.00 -6,850,000.00 -9,874,000.00
Profit Loss Attributable To Owners Of Parent -6,878,000.00 -6,850,000.00 -9,874,000.00
Profit Loss Attributable To Noncontrolling Interests 0.00 0.00 0.00
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -6,878,000.00 -6,850,000.00 -9,874,000.00
Adjustments For Income Tax Expense N/A 0.00 0.00 0.00
Adjustments For Decrease Increase In Inventories N/A -470,000.00 -887,000.00 -3,504,000.00
Adjustments For Increase Decrease In Trade Account Payable N/A -657,000.00 -304,000.00 355,000.00
Adjustments For Sharebased Payments N/A 139,000.00 49,000.00 196,000.00
Adjustments For Losses Gains On Disposal Of Noncurrent Assets N/A -20,000.00 -694,000.00 -66,000.00
Income Taxes Paid Refund Classified As Operating Activities N/A 0.00 0.00 0.00
Cash Flows From Used In Operating Activities N/A -8,368,000.00 -7,393,000.00 -8,212,000.00
Cash Flows From Used In Investing Activities N/A -2,050,000.00 -4,747,000.00 -7,286,000.00
Proceeds From Issuing Shares N/A 7,800,000.00 30,193,000.00 4,549,000.00
Proceeds From Borrowings Classified As Financing Activities N/A 7,470,000.00 1,391,000.00 1,492,000.00
Repayments Of Borrowings Classified As Financing Activities N/A 880,000.00 5,050,000.00 525,000.00
Interest Paid Classified As Financing Activities N/A 203,000.00 268,000.00 32,000.00
Cash Flows From Used In Financing Activities N/A 14,233,000.00 26,311,000.00 5,389,000.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes N/A 3,815,000.00 14,170,000.00 -10,116,000.00
Cash and cash equivalents 8,024,000.00 11,840,000.00 26,010,000.00 15,902,000.00

Please note that some sums might not add up.

Filings & Publications

  • Consolidated Report 2021 - Q4 French 🇫🇷

Insider Trades

Date Trading entity / Person Association Trade type Volume
19.06.2024 None Other Buy EUR 4,100.00
18.06.2024 None Other Other EUR 2,000,000.00
18.06.2024 None Other Other EUR 1,000,000.00
18.06.2024 None Other Buy EUR 42,200.00
30.06.2023 None Other Other EUR 0.00
30.06.2023 None Other Buy EUR 0.00

Capital Markets Information

ISIN

FR0011271600

LEI

9695007VNRQR6V5TMN85

Sub-Industry

Biotechnology

Listed Stock Exchange

Euronext Growth Euronext Paris

Contact Investor Relations Department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.